Or

Open access

NEWS - Oncology

Are We Being Misled About Precision Medicine? – The New York Times (10 articles per month are free)

“Doctors and hospitals love to talk about the cancer patients they’ve saved, and reporters love to write about them. But deaths still vastly outnumber the rare successes.”

 


Playing Doctor with Watson: Medical Applications Expose Current Limits of AI – Spiegel (free) (via @EricTopol)

“IBM has big plans for how its Watson artificial intelligence software could change the medical industry. But a number of hospitals have ended their experiments with the platform, arguing that it doesn’t help diagnose or treat diseases.”

 


The right diet can boost potency of cancer drugs – Nature News (free)

Original article: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors – Nature (link to abstract – $ for full-text)

Related: Top oncologist to study effect of diet on cancer drugs – The Guardian (free)

“Diets appear to matter in mouse cancer Rx – can these preclinical findings be translated to humans?” (via @Aiims1742 see Tweet)

 


Last Month in Oncology with Dr. Bishal Gyawali: June 2018 – eCancer News (free)

This review has an interesting opinion on changing definitions of clinically meaningful endpoints in cancer research.

 


Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Cabozantinib in Hepatocellular Carcinoma – NEJM Resident 360 (free)

Median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo, but the rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group.


ASCO 2018: Shortening Adjuvant Trastuzumab to 6 Months in Patients With HER2-Positive Early Breast Cancer Is Effective and Reduces Cardiac Toxicities – The ASCO Post (free)

Commentaries: Test of Herceptin Finds Briefer Treatment Can Work, With Fewer Side Effects – NPR (free) AND Shorter drug treatment OK for many breast cancer patients – Associated Press (free) AND For Women With Early Breast Cancer, Herceptin Treatment Can Be Much Shorter – The New York Times (10 articles per month are free)

““For women with early-stage breast cancer who needed the drug Herceptin, 6 months of treatment were as good as 12, a major study found. Less risk of side effects, less cost, less time “being a patient.”” (via @NYTHealth see Tweet)

 


Perspective: Demand cancer drugs that truly help patients – Nature (free)

“Drug regulators and trial designs should assess benefits that actually matter to people with cancer, says Ajay Aggarwal”

 


Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma – NEJM (link to abstract – $ for full-text)

Quick Take Video Summary: Sunitinib or Nivolumab plus Ipilimumab for Renal-Cell Carcinoma (free)

“Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab”.

 


Clinical Updates: Palliative radiotherapy – The BMJ (free)

Clinical Update for non-specialists on the benefits, practicalities, and side effects of palliative radiotherapy

 


Page 1 of 41234
Stay Updated in Your Specialty
No spam, just news
Unsubscribe with one click

 

Daily

Powered by Google TranslatorTranslator

 

Weekly or Less Often  (English Only)
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •